Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (267)	2/24/2003 7:38:29 AM
From: nigel bates	Read Replies (1) \| Respond to of 824

Alexion Completes Enrollment in Phase III Pivotal PRIMO-CABG Trial CHESHIRE, Conn., Feb. 24 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN - News) announced today that it has completed enrollment of its pivotal Phase III clinical trial of pexelizumab in approximately 3,000 patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB). The Phase III program, if successful, will be a key component supporting an NDA filing with the U.S. Food and Drug Administration. The trial, conducted by Alexion and Procter & Gamble Pharmaceuticals, its partner in the development of pexelizumab, is referred to as "Pexelizumab for Reduction in Infarction and Mortality in Coronary Artery Bypass Graft Surgery," or "PRIMO-CABG." "Completing enrollment of this Phase III pivotal trial for our lead drug candidate pexelizumab is an important milestone for Alexion," stated Leonard Bell, M.D., Chief Executive Officer of Alexion. "Full enrollment of this trial is significantly ahead of our aggressive internal schedule and we are very proud of the manner in which our clinical operations team executed enrollment of this large trial. Once follow-up patient visits and data collection are completed, we expect to analyze the data and report the results of this Phase III trial during the second half of this year." In this randomized, placebo-controlled trial, approximately 3,000 patients, at more than 200 clinical sites, undergoing coronary artery bypass graft surgery with cardiopulmonary bypass were treated with either placebo or pexelizumab bolus followed by a continuous infusion over 24 hours. The Phase III trial is designed to assess the safety and efficacy of pexelizumab in reducing the combined incidence of death or myocardial infarction in this patient population...